Investigational vaccine generates immune response to KRAS mutations in pancreatic cancer study
An investigational vaccine helped the immune system recognize and respond to mutations that drive most pancreatic cancers, according to results from a randomized phase 2 clinical trial led by Mayo Clinic researchers. The findings, published in Nature Medicine, will help researchers design a larger phase 3 clinical trial.
Read original article on Medical Xpress - latest medical and health news stories →Related news
-
Nearly one third of patients with advanced melanoma saw tumors disappear completely after receiving TIL therapy plus pembrolizumab immunotherapy
United Kingdom
-
Your Positive Weekly Horoscope: ‘Free Will Astrology’ by Rob Brezsny
United Kingdom
-
Ebola vaccine trial begins in DR Congo
United Kingdom
-
Kenya announces 2nd Ebola death, a close relative of the first patient
United Kingdom
-
Good News in History, October 24
United Kingdom
-
Newly discovered protein controls the space between mitochondrial membranes
United Kingdom
-
LGBTQ+ college students facing discrimination report higher mental health risks
United Kingdom
-
Ancient virus may help explain differences in human and chimpanzee brains
United Kingdom